Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Income from Continuing Operations of 92280000.0 for Q1 2026, down 26.0% year-over-year from 124702978.82 in Q1 2025, and down 57.89% quarter-over-quarter from 58447000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Income from Continuing Operations data on file, last reported at 92280000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 92280000.0, down 26.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 304084000.0 (up 22.35% YoY), and the FY2025 annual result was 285042000.0, up 38.82% from the prior year.
- Income from Continuing Operations slipped to 92280000.0 in Q1 2026 per MDGL's latest filing, from 58447000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 42239000.0 in Q2 2025 and troughed at 151971000.0 in Q2 2024.
- A 5-year average of 88952588.24 and a median of 85800000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 91.87% in 2024, then soared 72.21% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 85905000.0 in 2022, then plunged by 30.6% to 112194000.0 in 2023, then surged by 47.04% to 59416000.0 in 2024, then grew by 1.63% to 58447000.0 in 2025, then plunged by 57.89% to 92280000.0 in 2026.
- Business Quant data shows MDGL's Income from Continuing Operations at 92280000.0 in Q1 2026, 58447000.0 in Q4 2025, and 111118000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -92.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.28 Mn |
| Dec 31, 2025 | -58.45 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.24 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |
| Jun 30, 2021 | -61.65 Mn |